Introduction
Brinz Ophthalmic Solution 1% is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinz Ophthalmic Solution 1% is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Uses
Brinz Ophthalmic Solution 1% is a carbonic anhydrase inhibitor used for the reduction of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Associated Conditions
Pharmacodynamics
Used in the treatment of glaucoma, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Brinz Ophthalmic Solution 1% can decrease intraocular pressure by approximately 16-19% in patients with elevated intraocular pressure.
Mechanism of Action
Brinz Ophthalmic Solution 1% is a highly specific inhibitor of CA-II, which is the main CA isoenzyme involved in the secretion of aqueous humor. Inhibition of CA in the ciliary process of the eye slows the formation of bicarbonate, and reduces sodium and fluid transport. This results in a reduction in the rate of aqueous humor secretion and the intraocular pressure. Brinz Ophthalmic Solution 1% is absorbed systemically following topical ocular administration. Since it has a high affinity for CA-II, brinzolamide binds extensively to red blood cells, where CA-II is primarily found. As sufficient CA-II activity remains, adverse effects resulting from the systemic inhibition of CA by brinzolamide are not observed. The metabolite N-desethyl brinzolamide is also formed. This metabolite binds to CA and accumulates in red blood cells as well. In the presence of brinzolamide, the metabolite binds mainly to carbonic anhydrase I (CA-I).
Absorption
Absorbed into systemic circulation following topical ocular application
Protein Binding
Approximately 60%.
Half Life
111 days
Food Interactions
No interactions found.
Dosage
Pediatric Use: One drop in the affected eye(s) 2 times daily in pediatric patient (4 weeks to 5 years age)
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
